US 8138216
Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes
granted A61KA61K31/415A61P
Quick answer
US patent 8138216 (Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes) held by Jenrin Discovery, LLC expires Mon Mar 15 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Jenrin Discovery, LLC
- Grant date
- Tue Mar 20 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 15 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 36
- CPC classes
- A61K, A61K31/415, A61P, A61P1/00, A61P1/16